---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-040386"
form_type: "8-K"
ticker: "CBIO"
cik: "0001253689"
company_name: "CRESCENT BIOPHARMA, INC."
filed_at: "2025-04-29T23:59:59+00:00"
generated_at: "2026-05-23T03:30:17.704288+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# GlycoMimetics amends Crescent merger; exchange ratio ~15.42 GLYC shares per Crescent share

## Summary
- Amendment clarifies Crescent RSUs will be assumed using the same exchange ratio as other Crescent securities.
- Each Crescent share to receive approximately 15.4192 shares of GlycoMimetics common stock.
- Post-merger, GlycoMimetics holders expected to own ~2.6%; Crescent holders ~97.4% (fully diluted).
- GlycoMimetics net cash at closing assumed at $1.8 million for ownership calculation.
- Certificate of Designation for Series A Non-Voting Preferred Stock updated to clarify voting mechanics.

## SEC filing metadata
- accession: 0001104659-25-040386
- form_type: 8-K
- ticker: CBIO
- cik: 0001253689
- company_name: CRESCENT BIOPHARMA, INC.
- filed_at: 2025-04-29T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1253689/000110465925040386/0001104659-25-040386-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1253689/000110465925040386/tm2513409d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-040386
- JSON: https://secwatch.observer/filing/0001104659-25-040386.json
- Plain text: https://secwatch.observer/filing/0001104659-25-040386.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.